Online Pharmacy US » Phentermine

FDA approves Lannettâs generic for Sandoz weight-loss drug

drugs — Tue, 31 Aug 2010 10:44:58 +0000

The Food and Drug Administration granted marketing approval to Lannett Co. Inc. for its generic version of Phentermine hydrochloride, a weight-reduction medicine marketed by Sandoz. (Source: bizjournals.com Health Care:Health Insurance headlines)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

FDA approves Lannettâs generic for Sandoz weight-loss drug

drugs — Tue, 24 Aug 2010 17:49:36 +0000

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

FDA Gives Positive Review on Qnexa

drugs — Tue, 24 Aug 2010 16:48:15 +0000

The investigational obesity drug Qnexa (MedPage Today) — a combination of phentermine and topiramate — could become the first new prescription drug for paring pounds approved in several years, based on review documents relea sed today by the FDA. (Source: MedPage Today Primary Care)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Novel Weight-Loss Combo May Lower BP

drugs — Fri, 30 Jul 2010 04:31:05 +0000

Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic BP reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Clinical Endocrinology News)

ENDO: Novel Drug Combo May Aid in Weight Loss (CME/CE)

drugs — Fri, 30 Jul 2010 01:12:20 +0000

SAN DIEGO (MedPage Today) — A combination of phentermine and topiramate (Qnexa) appears to induce weight loss and a decrease in metabolic risk parameters for cardiovascular disease in obese patients, researchers reported here. (Source: MedPage Today Endocrinology)

MedWorm Message: Register for MedMatcha, MedWorm’s m edical advertising network, and receive $5 free advertising.

Novel Weight-Loss Combo May Lower BP

drugs — Fri, 23 Jul 2010 21:13:39 +0000

Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic blood pressure reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Family Practice News)

Lannett Receives FDA Approval For Phentermine Hydrochloride Capsules USP 30 Mg

drugs — Thu, 22 Jul 2010 06:33:34 +0000

Lannett Company, Inc. (NYSE AMEX: LCI) announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application ( ANDA) for Phentermine Hydrochloride Blue/White Seed Capsules USP, 30 mg, the generic equivalent of Sandoz, Inc.’s Reference Listed Drug (RLD) Phentermine Hydrochloride Capsules USP, 30 mg. According to Wolters Kluwer, U.S. sales of Phentermine Hydrochloride Capsules USP, 30 mg in 2009 were approximately $36.5 million at Average Wholesale Price (AWP)… (Source: Health News from Medical News Today)

Panel Votes Down New Diet Drug

drugs — Tue, 20 Jul 2010 22:16:44 +0000

GAITHERSBURG, Md. (MedPage Today) — An FDA advisory panel was divided over whether to recommend the approval of the investigational weight-loss drug phentermine/topiramate (Qnexa), but the Nay votes prevailed 10-6. (Source: MedPage Today Public Health)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and re ceive $5 free advertising.

FDA advisers reject anti-obesity drug QnexaÂ® (phentermine/topiramate) over safety concerns

drugs — Sun, 18 Jul 2010 02:48:24 +0000

Source: PharmaTimes
Area: News
PharmaT imes reports that advisers to the United States US Food and Drug Administration have voted 10-6 against recommending approval of the drug QnexaÂ® (phentermine/topiramate) for the treatment of obesity. Although the advisory panel did not dispute the effectiveness of the drug, the panel felt that the potential side effects such as depression, memory loss, increased heart rate and birth defects outweighed the benefits. The panel also expressed concern that, at just over 12 months, the data provided by the company were not long term enough. (Source: NeLM – News)

BP Dip With Novel Drug Combo Tied to Weight Loss

drugs — Thu, 15 Jul 2010 18:36:57 +0000

Market watch: Upcoming market catalysts in Q3 2010

drugs — Fri, 02 Jul 2010 10:33:46 +0000

Nature Reviews Drug Discovery 9, 507 (2010). doi:10.1038/nrd3225

Author: Michael Hay
Efforts to develop new anti-obesity drugs will face a critical test when two of the three therapies currently under consideratio n by the US FDA for regulatory approval â phentermine/topiramate (developed by Vivus) and lorcaserin hydrochloride (developed by Arena Pharmaceuticals) â come before FDA advisory committees (Source: Nature Reviews Drug Discovery)

New weight-loss drug combo on the horizon

drugs — Fri, 25 Jun 2010 00:53:40 +0000

For complete story visit theheart.org. (Source: theHeart.org)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free adver tising.

Different dosage of Lannett obesity drug OK’d

drugs — Wed, 09 Jun 2010 04:19:34 +0000

The Food and Drug Administration approved Lannett Co. Inc.'s application to market a generic 30-milligram version of a medication for the short-term management of obesity called phentermine hydrochloride. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

MedWorm Message: Register for MedM atcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Judge Rules Claimants Properly Sought Entry Into Show-Cause Proceeding

drugs — Tue, 01 Jun 2010 07:32:56 +0000

PHILADELPHIA – The judge supervising the American Home Products National Settlement has ruled that two claimants may procee d to a show-cause proceeding to argue for payment of claims approved nearly four years ago but later withdrawn (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Evaluating emerging issues in epidemiology.

drugs — Tue, 01 Jun 2010 01:57:20 +0000

Authors: Collins JJ, Bukowski JA, Weed DL, Brent RL, Klei n P, Boerstoel-Streefland M, Sprafka JM, Williams AL, Holsapple MP
Industry and government institutions need a credible approach for evaluating and responding to emerging public health issues. Representatives of industry, government, and academia met under the auspices of the International Life Sciences Institute’s Health and Environmental Sciences Institute (HESI) to develop successful strategies for dealing with emerging issues based on historical case studies. The case studies chosen for evaluation were (1) tampon use and to xic shock syndrome; (2) hazardous waste and childhood cancer risk in Toms River, New Jersey; (3) fenfluramine and phentermine use and valvular heart disease; (4) silicone breast implants and cancer and auto…

MDL Auditor Reports 553,000 Billable Hours In Common Benefit Work

drugs — Mon, 31 May 2010 19:25:06 +0000

PHILADELPHIA – The auditor who examines applications for common benefit fees in the diet drug multidistrict litigation reports that as of March 31, attorneys have spent more than 553,000 hours on common benefit work wi th a cumulative lodestar value of more than $156 million (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 12 03, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See March 2007, Page 5).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist.

drugs — Mon, 31 May 2010 17:19:51 +0000

This study assessed the potential pharmacokinetic interaction and safety/tolerability of taranaba nt and phentermine coadministration. This was a randomized, double-blind, 3-panel, fixed-sequence study in healthy participants. Panels A, B, and C evaluated the safety/tolerability of phentermine 15 mg coadministered with taranabant 0.5, 1, and 2 mg for 7 days (panel A) and 28 days (panels B and C). In panels A and C, phentermine 15 mg was administered both with (7 days, panel A; 28 days, panel C) and without (7 days) taranabant 0.5 mg or 2 mg to evaluate pharmacokinetics. The primary endpoint was phentermine AUC(0-24 h) in panels A and C. Secondary endpoints were changes from baseline in blood pressure and heart rate for all panels. The geometric mean ratios and 90% confidence intervals for p…

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and rece ive $5 free advertising.

Oxethazaine as the source of mephentermine and phentermine in athlete’s urine.

drugs — Mon, 31 May 2010 16:28:21 +0000

This study applied LC-MS-MS to analyze the excretions of three volunteers who ingested oxethazaine and presented positive results for mephentermine and/or phentermine. Thus, oxethazaine is the source of mephentermine and phentermine. Moreover, the results showed that 48 brands of gastric medicines containing oxethazaine were legally imported or locally manufactured in Taiwan, information which could be useful for limiting the misuse of oxethazaine by athletes. The data suggested that the sp orts associations should warn athletes about the risks of taking oxethazaine.
PMID: 19157735 [PubMed - as supplied by publisher] (Source: Forensic Science International)

Law Firm Attacks New Program Notice As Insufficient To Class

drugs — Mon, 31 May 2010 11:00:06 +0000

PHILADELPHIA – A Missouri law firm has objected to a jointly proposed procedure that would yield reduced benefits but faster resolution of nearly 90 percent of disputed Matrix claims, saying Court Approved Procedure (CAP) 15 does not provide class members with sufficient notice of how their claims would be handled (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docke t No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See December 2007, Page 4).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Wyeth Seeks Dismissal, Attorney Fees In Suits Claiming PPH Deaths

drugs — Mon, 31 May 2010 06:40:52 +0000

PHILADELPHIA – Wyeth has filed a motion to dismiss and seeking attorney fees in two lawsuits claiming wrongful death from primary pulmonary hypertension, saying the plaintiffs have no evidence that their decedents took Wyeth’s diet drugs (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, Carl D. Daniels v. Wyeth Inc., No. 06-20184, Horace Moore Sr. v. Wyeth Inc., No. 06-20187, E.D. Pa.).
Full st ory on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Unsuccessful Claimant: Diet Drug Settlement Is Unfair To Obese People

drugs — Mon, 31 May 2010 04:11:35 +0000

PHILADELPHIA – The American Home Products National Settlement as amended and interpreted by the supervising judge discriminates against obese persons and runs counter to accepted medical practice, an unsuccessful claimant argues to the Third Circuit U.S. Court of Appeals (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability L itigation, MDL Do cket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, Mary Schrodi v. AHP Settlement Trust et al., No. 07?2943, 3rd Cir.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Wyeth Argues Woman Does Not Have PPH, Fails To Prosecute

drugs — Mon, 31 May 2010 03:12:12 +0000

PHILADELPHIA – Wyeth Inc. has filed a motion to dismiss and for sanctions, arguing that a woman who asserts that the company’s diet drugs caused primary pulmonary hypertension (PPH) has failed to p rosecute after being told she does not have the disease (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Peggy Love v. Wyeth Inc., No. 2:06-cv-20067, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Trust Says Mediator Correctly Determined Claim’s Reduction Factors

drugs — Mon, 31 May 2010 02:02:38 +0000

PHILADELPHIA – The American Home Products Settlement Trust argues the diet drug court should affirm the decision of an arbitrator that a claimant who required surgery to correct severe aortic regurgitation had reduction factors in her medical record that require compensation at a lower level (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Cor p., No. 99-20593).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Judge Reverses 2 Benefit Denials, Upholds A 3rd

drugs — Mon, 31 May 2010 01:34:59 +0000

PHILADELPHIA – The judge supervising the American Home Products National Settlement has ordered the Settlement Trust to pay Matrix benefits to two former diet drug users, but affirmed the trust’s denial of benefits to a third (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Leg al News)

Judge Reverses Trust, Orders Benefits For 16 Matrix Claimants

drugs — Sun, 30 May 2010 23:36:56 +0000

PHILADELPHIA – Judicial reversals of the diet drug American Home Products Settlement Trust’s denials of Matrix benefits, virtually unheard of before February, have rapidly increased in recent months (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liab ility Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See August 2007, Pages 5 and 6 ).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Wyeth Opposes Opt Out By Woman Whose Records Were Lost In Katrina Flooding

drugs — Sun, 30 May 2010 07:40:00 +0000

PHILADELPHIA – Wyeth opposes a motion to opt out of the Seventh Amendment by a woman who claims that her medical records were lost in post-Katrina New Orleans, arguing that the loss of the records occurred after her decision to remain in the Seventh Amendment (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liabilit y Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See March 2007, Page 11).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Interneuron Seeks Dismissal After 7 Years Without Service Of Suit

drugs — Sun, 30 May 2010 04:34:47 +0000

PHILADELPHIA – Interneuron, the company that originally marketed Redux, has filed a motion to dismiss an individual plaintiff’s claims, saying that after nearly seven years, the plaintiff has yet to serve it with a complaint (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Lynn V. Thomas v. American Home Pr oducts Corp., et al., No. 00-21015, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Request For Protection Of Settlement Information Gets Expedited Handling

drugs — Sun, 30 May 2010 04:25:58 +0000

PHILADELPHIA – The judge supervising the diet drug multidistrict litigation has, at the request of Plaintiffs’ Liaison Counsel (PLC), ordered expedited handling of Wyeth’s request that individual settlement amounts not be filed with common benefit fee documentation and th at the judge instead inspect settlement information in camera (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, E.D. Pa.; See March 2007, Page 5).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Pro Se Claimants Seek Removal Of Class Counsel

drugs — Sun, 30 May 2010 02:32:23 +0000

PHILADELPHIA – Three pro se claimants have moved for the removal of class counsel, saying class members asserting claims for mitral regurgitation whose echocardiograms were don e by methods other than the color flow Doppler in an apical view specified in the Settlement Agreement constitute an unrepresented subclass (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See February 2007, Page 11).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Attorneys Representing Phentermine Manufacturers File Motion For Discharge

drugs — Sat, 29 May 2010 22:33:01 +0000

PHILADELPHIA – Lead and liaison counsel representing the manufacturers of the generic diet drug phentermine, the “phen” in “fen-phen,” have filed a motion for discharge, saying that after nine years, their work is done in the multidistrict litigation (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila B rown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Texas Attorney Renews Objection To Assessment, Common Benefit Fee Request

drugs — Sat, 29 May 2010 21:17:33 +0000

PHILADELPHIA – A diet drug attorney whose conflict of interest allegation regarding the distribution of common benefit fees was dismissed as premature but obtained a sympathetic concurring opinion in the Third Circuit U.S. Court of A ppeals has renewed his objection before the district court to the massive application for a final award of common benefit fees and costs (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See April 2005, Page 6).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Researchers Propose Combining Phentermine With Antidepressant Prozac

drugs — Sat, 29 May 2010 20:38:54 +0000

MADISON, Wis. – Researchers have recommended further study into a potential new weigh t loss drug cocktail involving phentermine, the “phen” in fen-phen, this time in combination with the antidepressant fluoxetine (Prozac) (International Journal of Obesity [2007] 31, 850 857).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Class Counsel Says Objectors Lack Standing, Misconstrue Fee Petition

drugs — Sat, 29 May 2010 18:01:58 +0000

PHILADELPHIA – Class counsel argues that objectors to its petition for a final award of more than $400 million in common benefit fees lack standing to object and misconstrue the law behind such fees and an agreement class counsel reached with more than 50 law firms that allowed the petition to go forward (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See October 2007, Page 6).
Full story on lexis.com (Source: Lexi sNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Claimant Opposes Show Cause Process

drugs — Sat, 29 May 2010 14:57:08 +0000

PHILADELPHIA – A claimant against the American Home Products National Settlement opposes the Settlement Trust in a show cause proceeding, arguing that her submission of two additional cardiologists’ opinions that she suffers moderate mitral valve insufficiency rebuts the trust’s fin ding that her attesting physician had no reasonable medical basis for the claim (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Parties Say Lapse In Auditor’s Certification Was Inadvertent, Harmless

drugs — Sat, 29 May 2010 13:41:55 +0000

PHILADELPHIA – Wyeth, class counsel and the American Home Products (AHP) Settlement Trust respond that a trust auditor’s lapse in board certification for cardiovascular disease was an inadvertent and harmless mistake that does not entitle a woman to Matrix benefits (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Shei la Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See August 2007, Page 8).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Lannett Receives FDA Approval For Phentermine

drugs — Sat, 29 May 2010 11:52:18 +0000

Lannett Company, Inc. (Amex:LCI) announced it has received approval from the U.S. Food and Drug Administration (FDA) for the company’s supplemental Abbreviated New Drug Application (ANDA) of Phentermine Hydrochloride Capsules 30 mg. The company expects to commence marketing this product immediately. Phentermine Hydrochloride (HCl) is indicated for the short-term management of obesity. [cl ick link for full article] (Source: Obesity / Weight Loss / Fitness News From Medical News Today)

Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity

drugs — Sat, 29 May 2010 09:19:55 +0000

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus’s Qnexa (the phentermine/topiramate combination) will earn Decision Resources’ propriet ary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the disease in 2011. Qnexa has competitive advantages in efficacy — it provides nearly double the weight-loss of current anti-obesity drugs — and improved delivery over the current clinical gold standard, Roche’s Xenical/GlaxoSmithKline’s OTC Alli… (Source: Health News from Medical News Today)

Wyeth Says Use Of Diet Drug Was An Illegal Act

drugs — Sat, 29 May 2010 06:53:55 +0000

PHILADELPHIA – Wyeth Inc. on Aug. 3 moved for summary judgment of a case asserting primary pulmonary hypertension (PPH), saying a widow’s claim that her husband u sed diet drugs prescribed for her constitutes an illegal act from which she may not profit (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Ragena J. Mize Crowe, et al. v. American Home Products Corporation, et al., No. 07-CV-20002-HB, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Positive results from phase III studies of QnexaT (phentermine and topiramate) as weight loss treatment

drugs — Sat, 29 May 2010 03:31:45 +0000

So urce: BioSpace
Area: News
VIVUS Inc. has announced positive results from two phase III 56-week studies (EQUIP and CONQUER) of its investigational weight loss treatment QnexaT, a once daily oral, controlled-release formulation of low dose phentermine and topiramate.

The phase III programme evaluated three doses of Qnexa (milligrams phentermine and controlled re lease topiramate, respectively): Qnexa 15/92 (full dose), Qnexa 7.5/46 (mid dose) and Qnexa 3.75/23 (low dose).

EQUIP was a randomised, double-blind, placebo-controlled, 3-arm, prospective trial in 1267 morbidly obese patients (1050 females and 217 males) from 93 centres in the US, with average baseline BMI 42.1 kg/m2 and baseline weight 256 pounds. They had a 4-week dose titration period followed by 52 weeks …

PAH Plaintiff Appeals Recommendation For Physical Examination

drugs — Sat, 29 May 2010 00:50:12 +0000

PHILADELPHIA – A woman asserting that Wyet h Inc.’s diet drugs caused pulmonary arterial hypertension has appealed a special master’s recommendation that the defendant be permitted to conduct a physical examination, saying the company’s expert has the information he needs to rebut her claims at trial (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Eldifonsa Soliz (Lillian Gomez) v. Wyeth, No. 2:004-cv-27321, E.D. Pa.; See May 2007, Page 8).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity

drugs — Fri, 28 May 2010 15:19:41 +0000

Court Redefines Special Master’s Responsibilities

drugs — Fri, 28 May 2010 11:27:44 +0000

PHILADELPHIA – Now that Special Master Gregory P. Miller has gone into the private practice of law with Philadelphia’s Drinker, Biddle & Reath, the judge supervising the diet drug multidistrict litigation has issued an order resolving potential conflicts between the special master’s new and continuing responsibilities (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; 2007 U.S. Dist. LEXIS 88962; See September 2007, Page 16).
Full st ory on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Special Master Says Wyeth Has Already Answered Admissions

drugs — Fri, 28 May 2010 07:01:24 +0000

PHILADELPHIA – The special master in the diet drug multidistrict litigation has recommended that Wyeth Inc. not be required to answer a plaintiff’s request for admissions (RFAs), saying the relevant information has already been produced in the MDL (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Angela Montgomery v. Wyeth Inc., et al., No. 06-20008, E.D. Pa.).
F ull story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Wyeth Seeks Dismissals Based On Plaintiffs’ Failure To Opt Out

drugs — Fri, 28 May 2010 04:34:57 +0000

PHILADELPHIA – Wyeth has filed motions to dismiss three lawsuits filed before approval of the national diet drug s ettlement, saying the plaintiffs are prohibited from suit because they failed to exercise opt outs required by the settlement (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Elizabeth A. and Bradley D. Bayliss v. A.H. Robins Inc., et al., No. 00-20434, Gary S. and Judy Miller v. Wyeth-Ayerst Laboratories, et al., No. 00-20435, Patricia and Joel Weiner v. American Home Products Corp., et al., No. 99-20614, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Special Master Recommends PPH Plaintiff Not Be Allowed To Pursue Claims At Trial

drugs — Fri, 28 May 2010 03:34:24 +0000

PHILADELPHIA – The diet drug special master on Dec. 31 recommended against allowing a plaintiff to assert primary pulmonary hypertension (PPH) at trial in the Philadelphia Court of Common Pleas, saying it is a settled claim because the plaintiff failed to rule out primary cardiac disease as a cause of her elevated pulmonary arterial pressure (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 120 3, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa., Nancy Cochran v. Wyeth, et al., No. 0002 75, Pa. Comm. Pls., Phila. Co.; See December 2007, Page 13).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Wyeth Says Plaintiff Never Opted Out

drugs — Thu, 27 May 2010 23:30:05 +0000

PHILADELPHIA – Wyeth on Aug. 31 moved to enforce the American Home Products National Settlement against a plaintiff it says never exercised an opt out (In Re: Diet Dr ugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sondi Krentler v. Wyeth-Ayerst Laboratories Co., et al., No. 00-20381, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Claimant Says Judge Redefined Pact To Make Recovery Harder

drugs — Thu, 27 May 2010 23:24:09 +0000

PHILADELPHIA – An unsuccessful claimant on June 15 said the judge supervising the American Home Products National Settlement has incrementally redefined the settlement ag reement to make it more difficult for those claiming injury from Wyeth’s diet drugs to receive benefits (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, Gay Patterson and Kenneth Patterson, Appellants, 3rd Cir. No. 07-1957; See March 2007, Page 7).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Judge: Trust’s Auditor Failed To Substantiate Mitral Valve Prolapse

drugs — Thu, 27 May 2010 21:23:00 +0000

PHILADELPHIA – The judge supervising the American Home Products N ational Settlement has reversed the settlement trust and ordered compensation of $551,721 on the A Matrix, ruling a trust auditor’s finding of mitral valve prolapse is insufficiently precise to quality as a reduction factor under the Settlement Agreement (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

The Longitudinal Effects of Fenfluramine-Phentermine Use

drugs — Thu, 27 May 2010 19:41:57 +0000

The use of previous anorectic medications and the combined use of the anorectic medications fenfluramine and phentermine (Fen-Phen) have been associated with varying degrees of valvular regurgitation and pulmonary hypertension. More recent reports have suggested a lower incidence of both than was previously reported. Comparisons of patients with similar body mass index (BMI) hav e been missing as well as information regarding chamber dimensions and pressures. Using transthoracic 2D, M-mode, and Doppler echocardiography, 57 men and women (30 Fen-Phen and 27 BMI-matched individuals/BMIMCG) were studied to determine their chamber dimensions, wall motion, diastolic function, valvular abnormalities, left ventricular ejection fractions (LVEFs), and pulmonary artery pressures (pAPs). The 30 Fen-Ph…

MedWorm Mes sage: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

AHP Trust Defends Denial Of Benefits In Matrix Claim Appeal

drugs — Thu, 27 May 2010 18:21:33 +0000

PHILADELPHIA – The trust administering the American Home Products National Settlement says it and the supervising judge were correct to deny Matrix compensation to a claimant because she does not have the requisite degree of valvular regurgitation (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, Gay Patterson and Kenneth Patterson, Appellants, 3rd Cir. No. 07-1957; See July 2007, Page 4).
Full story on lexis.com (Source: LexisNexis 74; Mealey’s™ Fen-Phen/Redux Legal News)

Trust Must Accept Claimant’s Registration Despite Late Filing

drugs — Thu, 27 May 2010 16:11:49 +0000

PHILADELPHIA – A law firm’s failure to place a class member’s registration for benefits in the mail by the deadline for registration was excusable neglect, the judge supervising the American Home Products National Settlement has ruled, and the trust must register her despite the tardiness (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Dock et No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Phentermine cardiovascular safety In response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. International journal of cardiology 2006;106:262-3.

drugs — Thu, 27 May 2010 13:18:39 +0000

Authors: Rothman RB, Hendricks EJ
A letter to the editor “Cusp tear in bicuspid valve possibly caused by phentermine” published in volume 106 (2006) stated “Phentermine is known to cause valvular disease with prolonged use.” There is no evidence that phentermine causes valvulopathy. Phentermine is the most widely us ed anti-obesity drug. In view of the serious cardiovascular risks associated with obesity, it is important to clarify that phentermine is a safe and effective anti-obesity medication.
PMID: 19189876 [PubMed - as supplied by publisher] (Source: International Journal of Cardiology)

Phentermine: Can it help me lose weight?

drugs — Thu, 27 May 2010 12:46:45 +0000

Phentermine may help kick-start your weight loss, but it’s not a permanent solution.Sponsored by:Chemotherapy.com – http://www.chemotherapy.com (Source: MayoClinic.com Full Feed)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Wyeth Says Reply Weakens Claim Of Excusable Neglect

drugs — Thu, 27 May 2010 08:43:17 +0000

PHILADELPHIA – Wyeth Inc. argues that a reply brief by two claimants undermines their claim of excusable neglect and shows that their failure to receive an important document was “nothing more than their law firm’s mailroom mishap” (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-P hen/Redux Legal News)

Wyeth Says Plaintiff Can’t Have Regurgitation And PPH At Same Time

drugs — Thu, 27 May 2010 08:05:07 +0000

PHILADELPHIA – Wyeth on Aug. 31 moved for dismissal of a plaintiff asserting primary pulmonary hypertension (PPH), saying measurements of the woman’s pulmonary arterial pressure do not support such a diagnosis (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-2 0593, Jennifer L. Cueva v. Wyeth, No. 2:04-CV-22451, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity

drugs — Thu, 27 May 2010 07:44:23 +0000

FDA Accepts Phase 3 Development Plan for Qnexa in Obese Patients

MOUNTAIN VI EW, Calif.–(HSMN NewsFeed)–VIVUS, Inc. (NASDAQ: VVUS ), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announ… BiopharmaceuticalsVIVUS, Qnexa, obesity, phentermine, topiramate (Source: HSMN NewsFeed)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Phentermine: Can prescription medication help weight loss?

drugs — Thu, 27 May 2010 04:05:05 +0000

Phentermine — Combine phentermine with diet and exercise to boost weight loss.
Sponsored by:Chemotherapy.com – http://www.chemotherapy.com (Source: MayoClinic.com – Ask a Specialist)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Parties Propose Procedure That Would Resolve Most Claims Held Up By Trust

drugs — Wed, 26 May 2010 22:29:59 +0000

PHILADELPHIA – The parties in the American Home Products National Settlement have proposed another procedure that would yield reduced benefits but faster resolution of nearly 90 percent of claims flagged by the Settlement Trust for alleged intentional manipulation of their supporting echocardiograms (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and recei ve $5 free advertising.

New Weight-Loss Drug Combo on the Horizon

drugs — Wed, 26 May 2010 20:36:55 +0000

The highest dose of an investigational weight-loss therapy, a combination of very low-dose phentermine and controlled-release topiramate, reduces body weight by around 10% after a year of treatment and has favorable effects on blood pressure, according to analyses presented at a late-breaking trial session. Heartwire (Source: Medscape Today Headlines)

Application for approval of Qnexa (phentermine and topiramate) for obesity submitted to the FDA

drugs — Wed, 26 May 2010 15:06:28 +0000

Source: BioS pace
Area: News
According to BioSpace, a New Drug Application (NDA) has been submitted to the US FDA seeking approval of QnexaÂ® (controlled-release oral formulation of low dose phentermine and topiramate) for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidaemia or central adiposity. The application follows the completion of a Phase III program, including two year-long studies (EQUIP and CONQUER). (Source: NeLM – News)

PPH Plaintiff Says Pulmonary Pressure Is A Jury Question

drugs — Wed, 26 May 2010 11:28:10 +0000

PHILADELPHIA – A plaintiff suing Wyeth for diet drug-induced primary pulmonary hypertension (PPH) says whether her pulmonary arterial pressure (PAH) would meet the requirements of the American Home Products National Settlement to assert the claim, in the absence of a drug she uses to reduce that pressure, is a question for the trier of fact (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, Jennifer L. Cueva v. Wyeth, No. 2:04-CV-22451, E.D. Pa.; See November 2007, Pa ge 12).
Full story on le xis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Judge Says Dispute Over Cause Of PPH Is An Issue Of Fact

drugs — Wed, 26 May 2010 06:44:25 +0000

PHILADELPHIA – Although a diet drug user must offer a reasonable scientific basis to assert a claim of primary pulmonary hypertension (PP H), it is not the role of the diet drug multidistrict litigation court to make a finding of fact on the relative credibili ty of the plaintiff’s and Wyeth’s experts, the MDL judge held Nov. 30 (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; Kathryn A. Decker, et al. v. Indevus Pharmaceuticals Inc., et al., No. 06-4461, Mass. Super.; 2007 U.S. Dist. LEXIS 88514; See December 2007, Page 13).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

How Physician Obesity Specialists Use Drugs to Treat Obesity.

drugs — Wed, 26 May 2010 06:34:55 +0000

Authors: Hendricks EJ, Rothman RB, Greenway FL
Specialist physicians may have prescribing habits that are different from nonspecialist physicians. Little is known about the prescribing habits of physicians specializing in the treatment of obesity. An anonymous survey was given to the physician members of the American Society of Bariatric Physicians (ASBP). There was a 35% response rate (266 physicians) to the questionnaire that was represented nationally. Almost all prescribed medications and all of them recommended phentermine. The average maximal dose of phentermine was above that approved in the package insert, and these physicians disagreed wi th the National Institutes of Health (NIH) Obesity Treatment Guidelines. Phendimetrazine, metformin, and phen termine plus L-5-hydroxytryptoph…

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Claimant Gets Benefit Despite Wyeth Doubt Of Her Use Of Drug

drugs — Wed, 26 May 2010 06:21:56 +0000

PHILADELPHIA – The judge supervising the American Home Products National Diet Drug Settlement on July 10 denied a Wyeth motion and ordered the Settlement Trust to pay benefits to a claimant whose use of the drugs Wyeth contested (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis. com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)

drugs — Wed, 26 May 2010 06:12:20 +0000

DETROIT, Aug. 22 (HSMN NewsFeed) — Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD ) announce d today that the US Food and Drug Administration (FDA) has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) for Phentermine… Biopharmaceuticals, Generics, FDACaraco Pharmaceutical, Phentermine, Adipex-P, TEVA Pharmaceutical (Source: HSMN NewsFeed)

Special Master Says No To Wyeth’s Designation Of A New Medical Expert

drugs — Wed, 26 May 2010 05:24:53 +0000

PHILADELPHIA – Wyeth should not be allowed to designate a new expert to opine that systemic sclerosis, and not its diet drugs, caused a plaintiff’s pulmonary arterial hypertension (PAH), the special master supervising the multidistrict litigation says in a Sept. 20 report and recommendation (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Eldifonsa Soliz (Lillian Gomez) v. Wyeth, No. 2:004-cv-27321, E.D. Pa.; See Jun e 2007, Page 6).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Judge Rules Trust Has Not Made Case For Reduction Factor

drugs — Wed, 26 May 2010 04:27:58 +0000

PHILADELPHIA – A former diet drug user who underwent mitral valve replacement surgery has been awarded nearly $700,000 in A Matrix benefits, overturning the trust’s contention that she should be paid about 20 percent of that amount based on the reduction factor of mitral annular calcification (MAC ) (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; 2007 U.S. Dist. LEXIS 82573).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Wyeth Files Motion Saying Plaintiffs May Not Sue The Company

drugs — Wed, 26 May 2010 02:32:43 +0000

PHILADELPHIA – Wyeth has moved for dismissal of six diet drug lawsuits, saying the plaintiffs never filed the required forms that would allow them to opt out of the national diet drug settlement to pursue such claims (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liabilit y Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Judge Amends Order To Eliminate Disclosure Of Private Settlements

drugs — Wed, 26 May 2010 01:33:04 +0000

PHILADELPHIA – After protests arrived from diverse parties, the judge supervising the diet drug multidistrict litigation on May 30 reversed an earlier decision and ruled that dollar amounts reached in settlements between Wy eth Inc. and individual plaintiffs should not be filed with common benefit fee documentation (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, E.D. Pa.; See May 2007, Page 4).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Special Master Says Measurements Needed To Assert PPH Claim

drugs — Wed, 26 May 2010 01:21:18 +0000

PHILADELPHIA – A plaintiff suing Wyeth for primary pulmonary hypertension (PPH) may not rely on the unsupported statement of a physician that but for her use of medication to reduce her pulmonary arterial pressure (PAP), she would meet the requirements of the National Settlement to assert the claim, the diet drug special master has recommended (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheil a Brown, et al. v. American Home Products Corp., No. 99-20593, Jennifer L. Cueva v. Wyeth, No. 2:04-CV-22451, E.D. Pa.; See September 2007, Page 8).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Review: Non-surgical management of obesity in adults

drugs — Wed, 26 May 2010 00:05:33 +0000

In this review in the New England Journal of Medicine, the authors present a case vignette followed by a discussion of the follow ing topics relating to the non-surgical management of obesity in adults:

â¢ Clinical problem
â¢ Evaluation
â¢ Lifestyle approaches (diet, physical activity, behavioural modification)
â¢ Pharmacological therapy (phentermine, diethylpropion, sibutramine, orlistat, rimonabant)
â¢ Maintenance of weight reduction
â¢ Areas of uncertainty
â¢ Guidelines (Source: NeLM Headline News)

Judge Overturns 2 Trust Denials, Affirms 2 Others

drugs — Tue, 25 May 2010 20:58:23 +0000

PHILADELPHIA – The judge supervising the American Home Products National Settlement has reversed the Settlement Trust’s denial of benefits to two claimants but affirmed denials in two other cases (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. Ame rican Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Wyeth Says Diagnoses Of PPH Do Not Meet Settlement’s Definition

drugs — Tue, 25 May 2010 20:05:56 +0000

PHILADELPHIA – Wyeth argues that to allow two plaintiffs whose pulmonary arterial hypertension (PAH) does not meet the settlement’s definition of primary pulmonary hypertension (PPH) to go to trial would “render the . . . protections for which Wyeth bargained a nullity” (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, Kathryn A. Decker, et al. v. Indevus Pharmaceuticals Inc., et al., Nancy Cochran v. Wyeth, et al., No. 000275, Pa. Comm. Pls., Phila. Co.; See November 2007, Page 11).
Full s tory on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Wyeth Tells Court Missing Physician Dooms PPH Claims

drugs — Tue, 25 May 2010 16:54:46 +0000

PHILADELPHIA – Saying the plaintiffs have failed to identify a prescribing physician nearly a year after fact discovery closed, Wyeth has filed for summary judgment against plaintiffs asserting that use of its diet drugs caused primary pulmonary hypertension (PPH) (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] P roducts Liability Litigation, MDL Docket No. 1203, Caroline Quesada and Manuel Quesada v. American Home Products, et al., No. 05-25778, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Phentermine cardiovascular safety

drugs — Tue, 25 May 2010 15:53:18 +0000

A recent case report published in the American Journal of E mergency Medicine described a 48-year-old woman with no significant medical history who developed a myocardial infarction and subsequent ventricular tachycardia/fibrillation. This patient also happened to be taking phentermine, and the aut hors therefore conclude âthat this agent, which is a chemical analogue of the potent amphetamine class of noradrenergic stimulants, may have the ability to promote potentially fatal cardiac outcomes.â We believe that the authors have left the reader with an unbalanced and exaggerated impression that phentermine is a dangerous drug. Because phentermine is commonly prescribed for the treatment of obesity, emergency medicine specialists deserve a more accurate discussion of the pharmacology and s…

PPH Plaintiffs’ Counsel Says Wyeth Misrepresents Its Positions In Pleadings

drugs — Tue, 25 May 2010 06:01:47 +0000

PHILADELPHIA – Counsel for five recently filed lawsuits alleging that Wyeth’s diet drugs caused primary pulmonary hypertension (PPH) after years of latency have filed a letter disputing Wyeth’s claim that the Complex Litigation Center in Pennsylvania Com mon Plea s Court, Philadelphia County, has no fast track for diet drug cases and other characterizations of their positions (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Helen Hill, et al., v. Wyeth, No. 07CV220, No. 07CV20025; Barbara Anderson v. Wyeth, No. 07CV214, No. 07CV20027; Joan Yovich v. Wyeth, No. 07CV216, No. 07CV20026; Linda Channels v. Wyeth, No. 07CV217, No. 07CV20024, E.D. Pa.; See April 2007, Page 6).
Full story on lexis.com (Source: LexisNexis® Mealey’…

Obesity in adults

drugs — Tue, 25 May 2010 04:22:48 +0000

New option(s) added for:

Diethylpropion New option for which we found one systematic review. The review found less weight loss with diethylpropion compared with phentermine. Data were from one small RCT and effects of diethylpropion in weight loss are unclea r. Categorised as Unknown effectiveness.

Mazindol New op tion for which we found no evidence. Categorised as Unknown effectiveness.

Bariatric surgery New option for which we found one systematic review. The review identified two RCTs and three cohort studies assessing the effects of various bariatric surgical techniques (gastric banding, gastric bypass, vertical banded gastroplasty, biliopancreatic diversion, and sleeve gastrectomy) in people with morbid obesity. All studies …

Parties: Auditor’s Lapsed Certification Was Inadvertent

drugs — Tue, 25 May 2010 03:34:58 +0000

PHILADELPHIA – Wyeth, class counsel and the American Home Products Settlement Trust have filed a motion that would leave standing the findings of a trust auditing cardiologist who allowed his board certification in cardiology to lapse during the time he was reviewing claims for the trust (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Hom e Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Judge Says Trust Must Pay Benefits On Diagnostic Close Call

drugs — Tue, 25 May 2010 01:47:40 +0000

PHILADELPHIA – Noting that the trust itself regarded the presence of mod erate mitral regurgitation (MR) as a close call, the judge supervising the American Home Products National Settlement has ordered the trust to pay $104,453 in Matrix B benefits to a woman with a variety of reduction factors (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Judge Says Claimant Should Not Pay For Trust’s Echo Failure

drugs — Tue, 25 May 2010 01:31:21 +0000

PHILADELPHIA – A claimant whose injury is worth $462,103 should not be penalized by the American Home Products Se ttlement Trust’s failure to provide an adequate echocardiogram, nor should the trust be allowed to use that substandard study to assert a reduction factor in the claimant’s compensation, the judge supervising the AHP National Settlement has ruled (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

New Obesity Drug Qnexa Showed Positive Results In Late Stage Trials Test Says Company

drugs — Mon, 24 May 2010 12:46:23 +0000

According to Vivus Inc, their experimental drug Qnexa for t reating obesity showed positive results in late stage trials, where patients who took the new diet pill, a combination of phentermine (a stimulant) and topiramate (an anticonvulsant), shed an average of nearly 15 per cent of their body (Source: Health News from Medical News Today)

Wyeth Says Plaintiff Can’t Provide Proof Of Diet Drug Use

drugs — Mon, 24 May 2010 01:23:12 +0000

PHILADELPHIA – Wyeth Inc. on June 18 moved to dismiss and for fees and costs, saying a plaintiff who alleges that his wife died of primary pulmonary hypertension (PPH) caused by the company’s diet drugs has no proof of their use (In Re: Diet Drugs [ Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, Roscoe A. Dellinger v. Wyeth, No. 06-20185, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Improper Opt-Out Suit Ruled A Bar To Woman’s Settlement Benefits Petition

drugs — Mon, 24 May 2010 00:36:13 +0000

PHILADELPHIA – The judge supervising the diet drug multidistrict litigation has ruled that a claimant’s failure to withdraw an improper opt-out suit against Wyeth was dismissed with prejudice, precluding her from later seeking settlement benefits (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; 2007 U.S. Dist. LEXIS 911 75).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Claimant: Trust, Auditor Hid Knowledge Of His Lapse In Certification

drugs — Mon, 24 May 2010 00:27:17 +0000

PHILADELPHIA – An unsuccessful matrix claimant has objected to allowing decisions by a trust auditor to stand, saying the trus t and the auditor have not been candid with the court about the circumstances surrounding the cardiologist’s lapsed board certification (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See July 2007, Page 6).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Antiobesity effects of the Î²-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats

drugs — Sun, 23 May 2010 23:06:07 +0000

Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats

International Journal of Obesity advance online publication, June 17, 2008. doi:10.1038/ijo.2008.91

Au thors: J D Roth, J L Trevaskis, J Wilson, C Lei, J Athanacio, C Mack, N C Kesty, T Coffey, C Weyer
& D G Parkes (Source: International Journal of Obesity)

Class Counsel Says Objector Slanders Them, Demonstrates Contempt

drugs — Sun, 23 May 2010 22:38:31 +0000

PHILADELPHIA – Class counsel has turned up the heat under a Texas attorney who oppo ses paying a common benefit fee in the diet drug multidistrict litigation as well as the size of the request for more than $400 million in common benefit fees, saying he has added to his alleged sins slander, contempt and violations of the Federal Rules of Civil Procedure (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See November 2007, Page 8).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Phentermine Diet Pills or What? Buying Legally and Safely Online

drugs — Sun, 23 May 2010 19:11:25 +0000

Internet pharmacy sites selling weight loss medications around the world are common, and often illegal according to many national regulatory bodies such as the DEA. Where a buyer resides dictates whether obesity medications such as Phentermine, the USA's most popular prescription diet pill, can be purchased legally online and from whom; e.g. unlicensed / non-US based pharmacies are prohibited in America (FDA/DEA). Up to now finding a web site to provide advice and pills such as Adip ex, Meridia, Xenical and Phentramin-d legally no matter where the buyer is resident was virtually impossible, hence the launch of phentermine-or-what.com (PRWeb Mar 3, 2010)
Read the full story at http://www.prweb.com/releases/2010/03/prweb3664334.htm (Source: PRWeb: Medi cal Pharmaceuticals)

Reduction Factor Is Binding, Regardless Of Other Echocardiograms

drugs — Sun, 23 May 2010 17:19:02 +0000

PHILADELPHIA – The judge supervising the American Home P roducts National Settlement has ruled that it is not necessary for all echocardiograms to reflect a reduction factor for a claimant to be placed on the B Matrix, where benefits are approximately 20 percent those in the A Matrix (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; 2007 U.S. Dist. LEXIS 85579).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Class Counsel Says Wyeth Changes Position On Test For PPH

drugs — Sun, 23 May 2010 06:33:10 +0000

PHILADELPHIA – Class counsel has weighed in on behalf of two plaintiffs asserting claims of primary pulmonary hypertension (PPH), saying Wyeth has reversed the position it took when it originally urged approval of the national diet drug settlement (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, Kathry n A. Decker, et al. v. Indevus Pharmaceuticals Inc., et al., No. unknown, Nancy Cochran v. Wyeth, et al., No. 000275, Pa. Comm. Pls., Phila. Co.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

The sale of weight-loss supplements on the Internet: A lurking health care crisis waiting to strike

drugs — Sun, 23 May 2010 04:44:56 +0000

Worldwide, obesity has assumed epidemic proportions. Between 2003 and 2 004, 32.2% of adults in the United States were classified as obese (body mass index â¥30 kg/m2). Many obese individuals have difficulty trying to lose weight using the conventional methods of diet and exercise, and, under mounting medical and societal pressures, many are compelled to seek an âeasy fixâ through pharmaceutical agents. The Internet has become a popular venue for the sale and purchase of su ch supplements, raising fears that lack of regulation may expose consumers to life-threatening risks. The use of pharmaceutical agents to help lose weight has had a checkered history. In 1997, the combined use of fenfluramine and phentermine led to the development of pulmonary hypertension and valvular heart disease,…

Class Counsel Says Settlement Echo Criteria Were Chosen As Generous

drugs — Sun, 23 May 2010 04:32:33 +0000

PHILADELPHIA – Class counsel has respon ded to three unsuccessful pro se claimants, saying that the echocardiogram criteria in the American Home Products National Settlement Agreement were chosen as the most likely to demonstrate compensable injury levels for most claimants and that other methodologies would not have yielded a bett er result for the three objectors (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See December 2007, Page 11).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Diet Drug Attorneys Apply For $403 Million In Common Benefit Fees

drugs — Sun, 23 May 2010 01:16:40 +0000

PHILADELPHIA – Calling it the “largest private-party settlement in the history of American litigation,” attorneys who administered the multidistrict litigation (MDL) over America n Home Products’ diet drugs and negotiated the settlement valued at more than $5 billion on July 16 applied for a $403 million final award of common benefit fees (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See June 2007, Page 4).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Late Echocardiograms Deemed Not To Be ‘Excusable Neglect’

drugs — Sat, 22 May 2010 23:44:44 +0000

PHILADELPHIA – The judge supervising the American Home Products National Settlement has denied benefits to two women whose private echocardiograms were performed after the settlement deadline; one of the women was suffering from mental illness around the time of the deadline and the other’s physician discouraged her from investigating whether the drugs had injured her (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brow n, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; 2007 U.S. Dist. LEXIS 86924).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Cardiac valvular pathology: comparative pathology and animal models of acquired cardiac valvular diseases.

drugs — Sat, 22 May 2010 22:19:09 +0000

Authors: Do nnelly KB
Recent voluntary withdrawal of the ergoline-derivative Alzheimers’ drug Pergolide (Permax) resulting from demonstrated risk of cardiac v alve injury illustrates the increased importance of valve injury in pharmaceutical toxicology. Following the 2001 landmark discovery of cardiac valve injury associated with the widely prescribed anti-obesity drug combination fenfluramine-phentermine, and subsequent withdrawal, the need to understand and assess cardiac valve biology and pathology both preclinically and clinically has been accentuated. Unique aspects of the developmental biology, anatomy, and physiology of cardiac valves compared to main cardiac tissue have been discovered, and key elements of the pathophysiology of various valvular injury mechanisms have been descri…

Judge Rules Trust Has Not Demonstrated Mitral Valve Prolapse

drugs — Sat, 22 May 2010 16:44:34 +0000

PHILADELPHIA – The judge supervising the American Home Products National Settlement has reversed the settl ement trust and ordered compensation of $733,670 on the A Matrix to a claimant who underwent surgery to replace the mitral valve (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Cardiac arrest in the setting of diet pill consumption.

drugs — Sat, 22 May 2010 13:18:10 +0000

Authors: Makaryus JN, Makaryus AN
The obesity epidemic currently plaguing the United States has spurred the development of a vast number of drugs to assist in the battle against obesity and its associated complications. The need to loose weight often ca uses patients to loose sight of or even ignore the serious side effects of some of the most widely used weight-loss medications. Here we present the case of ventricular tachycardia/fibrillation ar rest in an otherwise healthy 48-year-old woman who was taking no medications other than phentermine, a common appetite suppressant that functions as a central nervous system stimulant through activation of the noradrenergic pathway of the sympathetic nervous system.
PMID: 18606338 [PubMed - in process] (Source: The American Journal of Emerge…

Judge Says Echo Shows Regurgitation Before Aortic Surgery

drugs — Sat, 22 May 2010 12:51:16 +0000

PHILADELPHIA – An echocardiogram taken during surgery to replace a former diet drug user’s aortic valv e shows her level of regurgitation before surgery, entitling her to benefits, the judge supervising the American Home Products National Settlement has ruled (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Two Old Drugs Add Up to One New Diet Pill

drugs — Sat, 22 May 2010 02:20:58 +0000

Patients taking a novel diet drug that combines the stimulant phentermine with the anticonvulsant topiramate lost an average of 37 pounds over a year with significant improvement in a number of cardiovascular ri sk factors, according to an announcement from Vivus, the developer of the drug. (Source: MedPage Today Pediatrics)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Law Firms Seek Discovery Into Fee Agreement

drugs — Fri, 21 May 2010 12:47:53 +0000

PHILADELPHIA – Two law firms involved in diet drug litigation have moved for discovery into an agreement among major players whose goal was to avoid protracted wrangling over the final disbursement of a common benefit fee in the litigation (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See August 2007, Page 4).
Full story on lexis.com (Source: LexisNexis 4; Mealey’s™ Fen-Phen/Redux Legal News)

Class Counsel Says Lawyer Seeks Share Of Fee He Opposes

drugs — Fri, 21 May 2010 11:28:16 +0000

PHILADELPHIA – Class counsel says a Texas attorney who opposes paying a common benefit fee in the diet drug multidistrict litigation (MDL) has filed a lawsuit seeking to obtain a stake in another law firm’s share of that very fee (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See October 2007, Page 8).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Fen-Phen/Redux Legal News)

Me dWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Online Pharmacy US » Phentermine

FDA approves Lannettâs generic for Sandoz weight-loss drug

FDA approves Lannettâs generic for Sandoz weight-loss drug

FDA Gives Positive Review on Qnexa

Novel Weight-Loss Combo May Lower BP

ENDO: Novel Drug Combo May Aid in Weight Loss (CME/CE)

Novel Weight-Loss Combo May Lower BP

Lannett Receives FDA Approval For Phentermine Hydrochloride Capsules USP 30 Mg

Panel Votes Down New Diet Drug

FDA advisers reject anti-obesity drug QnexaÂ® (phentermine/topiramate) over safety concerns

BP Dip With Novel Drug Combo Tied to Weight Loss

Market watch: Upcoming market catalysts in Q3 2010

New weight-loss drug combo on the horizon

Different dosage of Lannett obesity drug OK’d

Judge Rules Claimants Properly Sought Entry Into Show-Cause Proceeding

Evaluating emerging issues in epidemiology.

MDL Auditor Reports 553,000 Billable Hours In Common Benefit Work

Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist.

Oxethazaine as the source of mephentermine and phentermine in athlete’s urine.

Law Firm Attacks New Program Notice As Insufficient To Class

Wyeth Seeks Dismissal, Attorney Fees In Suits Claiming PPH Deaths

Unsuccessful Claimant: Diet Drug Settlement Is Unfair To Obese People

Wyeth Argues Woman Does Not Have PPH, Fails To Prosecute

Trust Says Mediator Correctly Determined Claim’s Reduction Factors

Judge Reverses 2 Benefit Denials, Upholds A 3rd

Judge Reverses Trust, Orders Benefits For 16 Matrix Claimants

Wyeth Opposes Opt Out By Woman Whose Records Were Lost In Katrina Flooding

Interneuron Seeks Dismissal After 7 Years Without Service Of Suit

Request For Protection Of Settlement Information Gets Expedited Handling

Pro Se Claimants Seek Removal Of Class Counsel

Attorneys Representing Phentermine Manufacturers File Motion For Discharge

Texas Attorney Renews Objection To Assessment, Common Benefit Fee Request

Researchers Propose Combining Phentermine With Antidepressant Prozac

Class Counsel Says Objectors Lack Standing, Misconstrue Fee Petition

Claimant Opposes Show Cause Process

Parties Say Lapse In Auditor’s Certification Was Inadvertent, Harmless

Lannett Receives FDA Approval For Phentermine

Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity

Wyeth Says Use Of Diet Drug Was An Illegal Act

Positive results from phase III studies of QnexaT (phentermine and topiramate) as weight loss treatment

PAH Plaintiff Appeals Recommendation For Physical Examination

Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity

Court Redefines Special Master’s Responsibilities

Special Master Says Wyeth Has Already Answered Admissions

Wyeth Seeks Dismissals Based On Plaintiffs’ Failure To Opt Out

Special Master Recommends PPH Plaintiff Not Be Allowed To Pursue Claims At Trial

Wyeth Says Plaintiff Never Opted Out

Claimant Says Judge Redefined Pact To Make Recovery Harder

Judge: Trust’s Auditor Failed To Substantiate Mitral Valve Prolapse

The Longitudinal Effects of Fenfluramine-Phentermine Use

AHP Trust Defends Denial Of Benefits In Matrix Claim Appeal

Trust Must Accept Claimant’s Registration Despite Late Filing

Phentermine cardiovascular safety In response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. International journal of cardiology 2006;106:262-3.

Phentermine: Can it help me lose weight?

Wyeth Says Reply Weakens Claim Of Excusable Neglect

Wyeth Says Plaintiff Can’t Have Regurgitation And PPH At Same Time

VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity

Phentermine: Can prescription medication help weight loss?

Parties Propose Procedure That Would Resolve Most Claims Held Up By Trust

New Weight-Loss Drug Combo on the Horizon

Application for approval of Qnexa (phentermine and topiramate) for obesity submitted to the FDA

PPH Plaintiff Says Pulmonary Pressure Is A Jury Question

Judge Says Dispute Over Cause Of PPH Is An Issue Of Fact

How Physician Obesity Specialists Use Drugs to Treat Obesity.

Claimant Gets Benefit Despite Wyeth Doubt Of Her Use Of Drug

Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)

Special Master Says No To Wyeth’s Designation Of A New Medical Expert

Judge Rules Trust Has Not Made Case For Reduction Factor

Wyeth Files Motion Saying Plaintiffs May Not Sue The Company

Judge Amends Order To Eliminate Disclosure Of Private Settlements

Special Master Says Measurements Needed To Assert PPH Claim

Review: Non-surgical management of obesity in adults

Judge Overturns 2 Trust Denials, Affirms 2 Others

Wyeth Says Diagnoses Of PPH Do Not Meet Settlement’s Definition

Wyeth Tells Court Missing Physician Dooms PPH Claims

Phentermine cardiovascular safety

PPH Plaintiffs’ Counsel Says Wyeth Misrepresents Its Positions In Pleadings

Obesity in adults

Parties: Auditor’s Lapsed Certification Was Inadvertent

Judge Says Trust Must Pay Benefits On Diagnostic Close Call

FDA approves Lannettâs generic for Sandoz weight-loss drug

FDA approves Lannettâs generic for Sandoz weight-loss drug